Fused bicyclic heteroaromatic derivatives as kinase inhibitors
US9969748B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 11, 2015 |
| Grant date | May 15, 2018 |
| Priority date | — |
| Expiry date | Jun 11, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.